SBIR Phase II: ElectroNanospray Process for Nanoformulating Drugs

Nanocopoeia Inc., Saint Paul MN

Investigators

Abstract

This Small Business Innovation Research Phase II Project will develop a novel drug solubility enhancing process for improving yields from costly drug discovery efforts, where up to 40% of new drug candidates have poor water solubility and are abandoned despite promising biological activity. Phase I research developed a novel nanoformulation process using the ElectroNanospray process that improved model drug solubility 20-40 fold. In Phase II, the new process will be tested to enhance solubility of a model class of pain therapeutics, the non-steroidal anti-inflammatory drugs. By expanding the universe of potential drug candidates and by developing enhanced delivery methods for existing drugs the project will seek to enable the development of new drug therapies with an initial emphasis on pain management.